Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Evelo Biosciences Inc

(NASDAQ: EVLO)
Add to Portfolio
+0.12 (+2.04%)
as of Oct 11, 2019

Last 6.01
Change +0.12 (+2.04%)
Open 5.92
Prev. Close 5.89
Today's Range
5.92
6.72
52wk Range
4.90
15.89
Volume 49,900
Avg Volume 78,675
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
EVLO +2.04% -4.15% -44.20%
DJIA +1.21% +0.88% +7.04%
S&P 500 +1.09% +0.57% +8.87%

Key Statistics

Annual EPS -2.28
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 188,830
Weighted Alpha -57.50
Standard Deviation +0.53
Profit Margin N/A
Beta -0.17

Growth Rates

YTD -53.80%
1-Year -43.09%

Opinion

Sell Hold Buy

Recent Headlines

Evelo Biosciences to Present at the 2019 Cantor Global

GlobeNewswire via COMTEX - Thu Sep 26, 04:05PM EDT
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the 2019 Cantor Global (full story)
EVLO: 6.01 (+0.12)

Evelo Biosciences to Host Key Opinion Leader Symposium

GlobeNewswire via COMTEX - Fri Sep 20, 07:00AM EDT
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it will host a key opinion leader symposium on the unmet need in mild (full story)
EVLO: 6.01 (+0.12)

Evelo Biosciences Announces the Appointment of David

GlobeNewswire via COMTEX - Tue Sep 17, 07:01AM EDT
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, announced today that David Epstein has been appointed chairman of its Board of Directors. M(full story)
EVLO: 6.01 (+0.12)

Evelo Biosciences to Present at the Morgan Stanley

GlobeNewswire via COMTEX - Wed Sep 04, 07:27PM EDT
Evelo Biosciences, Inc. (Nasdaq:EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that management will participate in a fireside ch(full story)
MS: 41.93 (+0.88), EVLO: 6.01 (+0.12)

Evelo Biosciences Reports Positive EDP1815 Interim

GlobeNewswire via COMTEX - Tue Aug 06, 07:05AM EDT
-EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo-(full story)
EVLO: 6.01 (+0.12)